Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12405465 | 0.83 | FGFR4 (0.41) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL12405455 | 0.80 | CSNK2A1 (0.40) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL23554288 | 0.79 | CSNK2A1 (0.43) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL2492487 | 0.79 | FGFR4 (0.40) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL4928378 | 0.78 | CSNK2A1 (0.38) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL30007388 | 0.78 | CSNK2A1 (0.38) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL23530252 | 0.76 | CSNK2A1 (0.37) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL30918950 | 0.76 | FGFR4 (0.55) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL30918942 | 0.75 | CSNK2A1 (0.37) | FGFR4CSNK2A1CSNK2A2EGFRBTK | |
| SCHEMBL30895915 | 0.75 | FGFR4 (0.44) | FGFR4CSNK2A1CSNK2A2EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700592-B2 | α2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | FGFR4 3913/4885CSNK2A1 615/4885CSNK2A2 450/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | FGFR4 3913/4885CSNK2A1 615/4885CSNK2A2 450/4885 |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | FGFR4 3913/4885CSNK2A1 615/4885CSNK2A2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.